ArticleFrontiers in neurology2025
Two minimally invasive fusion techniques for neurogenic claudication caused by degenerative lumbar spondylolisthesis: a minimum 2-year follow-up study.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neurogenic claudication induced by degenerative lumbar spondylolisthesis (DLS) is a highly prevalent condition. In recent research, oblique lumbar interbody fusion with anterior fixation (OLIF-AF) has emerged as a favored minimally invasive approach for treating DLS. Nevertheless, there have been relatively few investigations that have compared this method with minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF), which has long been considered the standard technique. Aim: To compare the clinical and radiological outcomes of OLIF-AF and MIS-TLIF in patients suffering from single-level, low-grade degenerative lumbar spondylolisthesis that leads to neurogenic claudication. Methods: We conducted a retrospective study of 57 patients who presented with neurogenic claudication secondary to single-level degenerative lumbar spondylolisthesis and underwent surgical treatment between May 2018 and December 2022. Of these 57 patients, 31 underwent oblique lumbar interbody fusion with anterior fixation (OLIF-AF) and 26 underwent minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF). Every patient had a follow-up period of at least 2 years. The recorded and compared data included the perioperative indicators, follow-up outcomes, and imaging parameters between the two groups. Results: Preoperatively, the two groups exhibited a comparable baseline in demographic data and clinical characteristics, including visual analog scale (VAS) scores, Oswestry Disability Index (ODI), disc height (DH), intervertebral space angle (ISA), spinal canal cross-sectional area (CSA) and slip percentage (SP). Postoperatively, both groups exhibited significant improvements in VAS and ODI scores. The OLIF-AF group demonstrated superior clinical outcomes in terms of operative time (125.7 ± 46.2 min vs. 202.1 ± 66.4 min, Conclusion: Both OLIF-AF and MIS-TLIF are efficient in treating neurogenic claudication resulting from degenerative lumbar spondylolisthesis (DLS). Nevertheless, OLIF-AF is associated with a shorter operation duration, reduced surgical trauma, and faster early recovery, while maintaining long-term effectiveness and safety comparable to those of MIS-TLIF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.